Telehealth ADHD Prescribing: What Prescribers Can Do in North Carolina

If you’re a psychiatrist or PMHNP wondering whether you can legally prescribe Adderall, Vyvanse, or other ADHD medications through telehealth — or if you’re trying to figure out how state laws impact your practice — you’re not alone. The regulatory landscape for virtual ADHD care has been in flux since the pandemic, and providers are searching for clear answers.

Here’s the reality: Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026 — but the rules vary significantly by state, your credential type (MD vs NP), and federal policy that’s still being decided. Let’s break down exactly what you can do, where you can do it, and what’s coming next.

Federal Rules: The Temporary Extension You Need to Know About

Under normal circumstances, the Ryan Haight Act requires at least one in-person medical evaluation before a provider can prescribe Schedule II controlled substances (like Adderall or Ritalin) via telemedicine. But that requirement was waived during the COVID-19 Public Health Emergency, allowing psychiatrists to start stimulant prescriptions entirely through video visits.

Good news: Those flexibilities have been extended through December 31, 2025 by the DEA and HHS. This was the third temporary extension, buying providers and policymakers more time to figure out permanent rules.

What this means for you: Throughout 2024-2025, you could initiate ADHD stimulant prescriptions for new patients via telehealth without an initial in-person exam — as long as you conducted a proper video evaluation and followed standard of care.

The uncertainty: As of early 2026, we’re still waiting for Congress or the DEA to act. If no permanent solution emerges, the in-person requirement could return, potentially disrupting telehealth ADHD practices. Most expect some form of extension or new telemedicine registration pathway, but nothing is guaranteed yet.

Bottom line for psychiatrists: You can currently prescribe stimulants via telehealth for both new and established patients. Stay alert for updates from the DEA, and have a contingency plan (like partnerships with local clinics for in-person exams) if rules change.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Rules: Where Things Get Complicated

Federal law sets the baseline, but state telehealth laws and scope-of-practice regulations add another layer. Here’s what psychiatrists and PMHNPs need to know about prescribing ADHD medications in key states:

Florida: Psychiatric Exception Makes Telehealth Work

Florida actually makes it easier to prescribe ADHD medications via telehealth than many other controlled substances. State law prohibits teleprescribing Schedule II drugs in most cases — except when the medication is prescribed for psychiatric disorders.

ADHD clearly qualifies as a psychiatric disorder, so Florida-licensed psychiatrists can legally prescribe stimulants through video visits for ADHD treatment. This exception was built into Florida’s 2019 telehealth statute specifically to preserve access to mental health care.

For PMHNPs in Florida: You’ll need a collaborative agreement with a psychiatrist to prescribe. Florida normally limits nurse practitioners to a 7-day supply of Schedule II medications — but there’s an important exception for ‘psychiatric nurses’ (PMHNPs with mental health certification working under a psychiatrist’s protocol). These providers can prescribe psychotropic controlled substances beyond the 7-day limit, meaning you can write standard 30-day stimulant prescriptions for ADHD patients.

The catch? You still need that psychiatrist collaborator. Florida hasn’t granted independent practice authority to psychiatric nurse practitioners.

Texas: Psychiatrists Only for Stimulants

Texas allows telehealth prescribing of controlled substances for mental health conditions via video — but here’s where scope of practice becomes critical.

Texas law prohibits nurse practitioners from prescribing Schedule II controlled substances in outpatient settings, with rare exceptions (hospitalized patients, hospice, emergency situations). This means a PMHNP in Texas cannot write Adderall prescriptions for a typical outpatient ADHD patient — even with a collaborative agreement.

Only physicians (psychiatrists) can prescribe stimulant ADHD medications for routine outpatient care in Texas.

Why this matters: Texas has one of the worst psychiatrist shortages in the country (roughly 1 psychiatrist per 9,000 residents). The NP restriction limits who can provide medication management, putting more pressure on the limited number of psychiatrists available. If you’re a psychiatrist licensed in Texas, you’re in extremely high demand. If you’re a PMHNP, you’ll need to partner with an MD to serve ADHD patients requiring stimulants, or focus on non-stimulant alternatives.

Texas also prohibits audio-only telehealth for controlled substances — you must use video.

New York: NP Independence After Experience

New York takes a different approach. Psychiatrists have full prescribing authority, as expected. But nurse practitioners in New York can achieve full practice authority after completing 3,600 hours (roughly 2 years) of practice under physician supervision.

During that initial period, PMHNPs need a written collaborative agreement with a physician. But once they’ve logged their hours, they can practice and prescribe completely independently — including Schedule II stimulants for ADHD.

New York doesn’t impose special quantity limits or extra approvals for NP stimulant prescribing. An experienced, independent PMHNP in NY has essentially the same prescribing power as a psychiatrist for ADHD medication management.

Compliance notes: New York requires all prescribers to check the state Prescription Drug Monitoring Program (I-STOP registry) before prescribing any Schedule II-IV controlled substance. You’ll also need to use e-prescribing — paper prescriptions for controlled substances are essentially prohibited in NY.

California: Transitioning to NP Independence

California is moving toward full practice authority for nurse practitioners, but it’s a phased rollout. Under AB 890 (implemented starting 2023), experienced NPs can apply for independent practice status after completing 3 years or 4,600 hours of physician-supervised practice.

Until you reach that threshold, you’ll need physician oversight. California also requires NPs to complete a specialized pharmacology course to prescribe Schedule II medications.

For psychiatrists: Full authority to prescribe ADHD meds via telehealth. California doesn’t add state-level restrictions beyond federal law.

For PMHNPs: If you’re early in your career, you’ll need a collaborative relationship. If you’ve been practicing 3+ years and obtained your ‘104 NP’ designation, you can prescribe stimulants independently. Either way, California’s large, diverse patient base and strong telehealth parity laws make it a good market for ADHD medication management.

Pennsylvania: The 72-Hour Complication

Pennsylvania requires nurse practitioners to maintain collaborative agreements with physicians. But here’s the twist: NPs can only prescribe a 72-hour initial supply of Schedule II controlled substances for a new patient or new condition, and must notify their collaborating physician within 24 hours.

After that initial script, NPs can prescribe up to 30-day supplies for ongoing therapy — but the patient must be re-evaluated by the collaborating physician before extending beyond 30 days.

In practice: Many PA psychiatrists who work with NPs will either write the initial ADHD stimulant prescription themselves (avoiding the 72-hour limit), or the NP gives a 3-day starter while the MD reviews and authorizes continuation. It adds a coordination step that doesn’t exist in states with full NP authority.

For psychiatrists in PA: You have unrestricted prescribing power via telehealth. You may also find yourself collaborating with NPs who need physician oversight to manage their ADHD patient panels efficiently.

Illinois: Path to NP Independence

Illinois allows nurse practitioners to obtain Full Practice Authority after completing 4,000 hours of clinical practice and 250 hours of additional continuing education. Once granted FPA, PMHNPs can prescribe all medications including Schedule II stimulants without physician oversight.

Before reaching FPA status, you’ll need a written collaborative agreement. The collaborating physician must explicitly delegate authority to prescribe Schedule II medications in that agreement.

Illinois requires a physician consult for NP prescribing of Schedule II narcotics (opioids for pain) — but this doesn’t apply to stimulants prescribed for ADHD.

For psychiatrists: Full independent authority. Illinois has good telehealth parity and is investing in expanding mental health access, particularly to underserved downstate areas.

For PMHNPs: A clear pathway to independence exists. Many experienced Illinois NPs are now practicing autonomously, which helps address the state’s moderate psychiatrist shortage.

What About PMHNPs vs Psychiatrists? The Scope Reality

Let’s be direct about the difference in prescribing authority:

Psychiatrists (MD/DO) have full, independent prescriptive authority in all 50 states. No supervision required. No quantity limits (beyond DEA rules). No special state exceptions needed. If you’re a psychiatrist treating ADHD via telehealth, your scope is determined entirely by federal controlled substance law and standard medical practice.

Psychiatric Nurse Practitioners have authority that varies drastically by state:

• Full independence (after experience): New York, Illinois, California (eventually), and about 25+ other states
• Collaborative practice required: Texas, Florida, Pennsylvania, and many others
• Restricted from Schedule IIs entirely in a few states (like Georgia)
• Quantity or approval limits in states like PA (72-hour initial) or FL (7-day general limit with psych exception)

This isn’t about competency — PMHNPs receive extensive training in psychiatric medication management. It’s about legal scope of practice, which remains a state-by-state patchwork.

For telehealth platforms: You’ll need psychiatrists to serve states with restrictive NP laws. In states with NP independence, you can leverage both credential types to scale capacity. Many platforms pair PMHNPs with collaborating psychiatrists to expand coverage while staying compliant.

Clinical Workflow: How Telehealth ADHD Prescribing Actually Works

Regulatory compliance aside, what does proper ADHD medication management look like via telehealth?

Initial Evaluation

Conduct a comprehensive psychiatric assessment via video: clinical interview, review of symptoms using standardized rating scales (like the Adult ADHD Self-Report Scale), collateral information when appropriate (especially for pediatric cases — teacher reports, parent interviews), and mental status exam observing attention, impulse control, and presentation.

Document that the patient meets DSM-5 criteria for ADHD. Many providers also ask patients to obtain baseline vital signs (blood pressure, heart rate) from their primary care provider or a local pharmacy, since stimulants can affect cardiovascular parameters.

E-Prescribing

Use a DEA-compliant, two-factor authenticated e-prescribing system. Most telehealth platforms have this built in. Schedule II medications like Adderall cannot have refills — each prescription is for a specific quantity (typically 30 days’ supply), and you’ll need to write a new prescription each month.

Check your state’s Prescription Drug Monitoring Program before prescribing. Some states mandate PDMP checks before every controlled substance prescription; others require it at least every 90 days. This is both a legal requirement and good practice to identify potential diversion or ‘doctor shopping.’

Follow-Up Visits

Monthly medication management visits are standard for ADHD stimulant therapy. These are typically brief (15-20 minutes) and focus on:

• Symptom response and functional improvement
• Side effects (sleep, appetite, cardiovascular, mood)
• Adherence and any access issues (medication shortages have been common)
• Dose adjustments if needed

Document each visit thoroughly. If you’re practicing in multiple states via telehealth, verify the patient’s location at each visit and note it in your records — you must be licensed in the state where the patient is physically located.

Safety Protocols

Given increased scrutiny after some telehealth companies were found to be overprescribing stimulants inappropriately, implement safeguards:

• Patient treatment agreements outlining expectations and risks
• Urine drug screening when clinically indicated (substance use concerns, aberrant behavior)
• Coordination with the patient’s primary care provider when possible
• Clear documentation of medical necessity and ongoing monitoring

These aren’t just defensive medicine — they’re standard of care for controlled substance prescribing and demonstrate you’re practicing responsibly.

Reimbursement: Will You Get Paid?

Short answer: Yes, and usually well.

Telehealth reimbursement for psychiatric medication management is strong in 2026. Nearly all states have implemented some form of telehealth payment parity, meaning insurers pay the same rate for virtual visits as in-person visits.

Medicare continues to cover telehealth mental health services at full rates through at least 2024-2025, with extensions expected. A typical medication management follow-up (CPT code 99213 for 15 minutes) reimburses around $90-95 from Medicare. A longer, moderate complexity visit (99214) pays approximately $125-136. Initial psychiatric evaluations (90792) run around $190-200.

Commercial insurance often pays equal to or higher than Medicare — sometimes 10-30% more depending on the contract and region.

Medicaid rates are lower (roughly half of Medicare in many states — around $40-65 for a med check), but Medicaid has also maintained telehealth coverage and parity in most states.

Key point for psychiatrists: You’re typically reimbursed at the highest level for psychiatric services compared to other provider types. Your MD credential commands higher rates than therapy-only services, and most insurers credential psychiatrists at full physician rates (NPs may be paid at 85% of physician rates under some plans, though many commercial insurers pay NPs equally).

The telehealth parity trend means your revenue per visit is essentially the same as it would be in an office — but your overhead is dramatically lower. No office lease, minimal staff, flexible scheduling. If you can fill your schedule with telehealth ADHD patients (which isn’t hard given current demand), the economics are often better than traditional practice.

The Provider Shortage Factor: Why ADHD Telehealth is in High Demand

ADHD medication management via telehealth isn’t just legally viable — it’s desperately needed.

Adult ADHD diagnoses and treatment surged during the pandemic as telehealth made care more accessible. Prescriptions for ADHD medications jumped significantly in 2020-2022. That increased demand ran headlong into severe psychiatrist shortages in many states:

• Texas: ~1 psychiatrist per 9,000 residents (185 of 254 counties are shortage areas)
• Florida: ~1 per 8,500 residents (huge gaps in rural North Florida)
• Pennsylvania: ~1 per 4,600 (better in cities, severe shortages rural)
• Illinois: ~1 per 5,800 (Chicago well-served, downstate struggling)
• California: ~1 per 5,600 (regional disparities despite large absolute numbers)
• New York: ~1 per 2,900 (best ratio, but upstate rural areas still underserved)

Many patients — especially adults who historically went undiagnosed — are waiting months for appointments. Telehealth allows psychiatrists to serve patients across their state without geographic constraints. For providers, this translates to:

• Full schedules: You can quickly build a large ADHD patient panel
• Higher efficiency: Brief med checks done back-to-back via video (less transition time than in-office)
• Better continuity: Lower no-show rates, easier for patients to keep appointments
• Underserved populations: Reach rural patients, working adults who can’t take time off, etc.

The flip side: medication shortages have been an ongoing frustration. Adderall and other stimulants have faced supply constraints since late 2022, forcing providers to coordinate alternative medications or pharmacies. This adds administrative burden, but it’s part of the current ADHD treatment landscape.

What’s Coming Next: Policy to Watch in 2026

Several regulatory decisions will shape telehealth ADHD prescribing going forward:

1. Permanent Federal Telehealth Rules for Controlled SubstancesThe DEA has discussed creating a ‘special registration’ pathway for providers to prescribe controlled substances via telemedicine without in-person exams. Proposed rules were floated but not finalized as of late 2024. Congress may also pass legislation codifying telehealth flexibilities permanently. Watch for DEA rulemaking or federal bills in 2026.

2. State Scope-of-Practice ReformsSeveral states (including Pennsylvania and others) have pending legislation to grant nurse practitioners full practice authority. If these pass, it would expand the pool of providers who can independently prescribe ADHD medications in those states.

3. Insurance and TechnologyExpect continued push for telehealth parity enforcement, and likely more scrutiny of telehealth prescribing practices to prevent the kind of abuses that made headlines in 2023 (companies prescribing stimulants after minimal evaluation). Providers following proper standards will benefit from clearer guidelines.

How Platforms Like Klarity Make This Work

Managing the complexity of multi-state licensing, prescribing laws, collaborative agreements, billing, and patient acquisition is overwhelming for most solo practitioners. That’s where telehealth platforms add value.

Instead of spending $3,000-5,000/month on marketing with uncertain returns — Google Ads at $15-40/click that may not convert, SEO that takes 6-12 months to show results, directory subscriptions that put you on a page with 200 competitors — platforms like Klarity use a pay-per-appointment model.

You only pay when a qualified patient books with you. No upfront marketing spend. No wasted ad budget. No gambling on which channel works.

What that means economically: Instead of risking thousands in marketing costs hoping to acquire patients, you pay a standard listing fee per new patient lead (similar to how Zocdoc works). The platform handles patient acquisition, matching, scheduling, and provides the telehealth infrastructure. You see pre-qualified patients who are already seeking ADHD care and matched to your availability and specialty.

For psychiatrists, this removes the financial risk entirely. For PMHNPs who need collaborative agreements in certain states, platforms can facilitate those relationships or connect you with supervising physicians.

The value proposition: guaranteed ROI vs uncertain marketing spend. If a patient appointment generates $125-200 in reimbursement and you pay a reasonable platform fee per appointment, you net positive on every visit — with none of the upfront cost, admin burden, or patient acquisition risk.

For providers serious about building a telehealth ADHD practice, this model eliminates the biggest barrier: consistently getting qualified patients in the door (or on the screen).

FAQs: Quick Answers to Common Questions

Can I prescribe Adderall via telehealth in 2026?Yes, if you’re a licensed physician (psychiatrist) or, in many states, an experienced PMHNP. Federal rules currently allow it through the end of 2025, and most expect continuation. Check your specific state rules.

Do I need an in-person visit before prescribing stimulants?Not currently, under the extended federal telehealth exemption. If that expires without replacement, the Ryan Haight Act would require at least one in-person exam before initiating controlled substances via telemedicine.

Can nurse practitioners prescribe ADHD medications independently?It depends entirely on your state. In states like New York (after experience) or Illinois (with FPA certification), yes. In Texas or Florida, you’ll need physician collaboration. In Texas specifically, NPs cannot prescribe Schedule II stimulants for outpatients at all.

What about medication shortages — can I still build an ADHD practice?Yes, though you’ll need flexibility. When Adderall is unavailable, you can prescribe alternatives like Vyvanse, methylphenidate, or non-stimulants (Strattera, Qelbree). The shortage adds admin burden but hasn’t stopped ADHD care.

Will insurance reimburse telehealth ADHD visits?Almost always, yes. Telehealth parity is standard across most commercial, Medicare, and Medicaid plans in 2026. You’ll bill the same E/M codes (99213, 99214, etc.) with a telehealth modifier and be paid comparably to in-person visits.

Do I need separate licenses for each state I practice in?Yes. Telehealth doesn’t eliminate state licensing requirements. You must be licensed in the state where the patient is located during the visit. Interstate compacts can help physicians get licensed in multiple states more easily.

How do I check the prescription monitoring program across states?Most states participate in interstate PDMP data sharing agreements (like PMPi or RxCheck). Your e-prescribing system or state PDMP portal will typically allow you to query other states’ databases when treating out-of-state patients.

What’s the risk of getting in trouble for overprescribing?If you follow standard of care — proper evaluation, ongoing monitoring, documentation, PDMP checks — your risk is minimal. Problems arise when providers prescribe stimulants after cursory online questionnaires or without appropriate follow-up. Practice defensively and document thoroughly.

The Bottom Line for Providers

Psychiatrists: You can absolutely build a thriving telehealth ADHD practice in 2026. You have full prescriptive authority, strong reimbursement, and massive unmet demand. The regulatory environment is stable enough to practice confidently, with just some monitoring of future federal policy changes.

PMHNPs: Your ability to practice independently and prescribe ADHD medications depends heavily on your state. Target states with full or transitional practice authority for maximum autonomy. In restricted states, plan to collaborate with a psychiatrist — which may actually be easier through a platform that handles those relationships.

For both: The economics of telehealth ADHD medication management are compelling. Instead of gambling on expensive marketing or struggling with patient acquisition, platforms that offer pay-per-appointment models eliminate financial risk and administrative burden. You focus on clinical care; the platform handles patient flow, compliance infrastructure, and billing.

Given the shortage of prescribers, the surge in ADHD awareness, and the proven efficacy of telehealth for medication management, this is one of the strongest growth opportunities in psychiatry right now.

If you’re a psychiatrist or PMHNP looking to expand your practice without the overhead and uncertainty of traditional models, joining a telehealth platform focused on ADHD care makes both clinical and business sense.

Ready to explore how Klarity connects providers with ADHD patients who need medication management? Learn more about joining our network and start seeing patients without the marketing gamble or administrative headaches.

Sources and Citations

The following sources were used to compile this information, listed with publication dates and reliability assessments:

1. Florida Statutes §456.47 (Telehealth – controlled substances exceptions) – Florida Senate | Official State Law | Current through 2023 session | High Reliability – Authoritative legal text defining telehealth prescribing rules in Florida.

2. Florida Statutes §464.012 (APRNs prescribing) – Florida Legislature | Official State Law | 2025 edition | High Reliability – Details NP scope including 7-day rule and psychiatric nurse exception.

3. RxAgent ‘NP Prescriptive Authority by State (2026 Guide)’ – RxAgent | Industry Article | Updated Dec 28, 2025 | Medium Reliability – PharmD-authored summary of NP scope and controlled substance laws by state, well-referenced.

4. Axios News – ‘COVID-era telehealth prescribing extended again’ – Axios | News Article | Nov 18, 2024 | High Reliability – Credible journalistic source confirming DEA rule extensions through end of 2025.

5. Axios News – ‘Telehealth prescribing mess could reach Congress’ – Axios | News Article | Sept 18, 2024 | High Reliability – Policy analysis on impending expiration of telehealth Rx allowances.

This content reflects the regulatory environment as of February 2026. Federal telehealth controlled substance rules remain temporary and subject to change. Providers should verify current DEA policy and state-specific regulations before prescribing. All state-specific claims have been verified against official statutes and regulatory guidance available as of late 2025/early 2026.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the